184 related articles for article (PubMed ID: 28194436)
41. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
42. High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.
Lee LH; Krupski C; Clark J; Wunderlich M; Lorsbach RB; Grimley MS; Burwinkel M; Nelson A; Kumar AR
Blood Adv; 2020 Feb; 4(4):717-727. PubMed ID: 32092141
[TBL] [Abstract][Full Text] [Related]
43. Langerhans-Cell Histiocytosis.
Allen CE; Merad M; McClain KL
N Engl J Med; 2018 Aug; 379(9):856-868. PubMed ID: 30157397
[No Abstract] [Full Text] [Related]
44. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
45. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
46. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
47. CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition.
Diamond EL; Francis JH; Lacouture ME; Rotemberg V; Yabe M; Petrova-Drus K; Ulaner GA; Reddy R; Abdel-Wahab O; Durham BH
Leukemia; 2023 Aug; 37(8):1737-1740. PubMed ID: 37355734
[No Abstract] [Full Text] [Related]
48. Protein kinases: drug targets for immunological disorders.
Castelo-Soccio L; Kim H; Gadina M; Schwartzberg PL; Laurence A; O'Shea JJ
Nat Rev Immunol; 2023 Dec; 23(12):787-806. PubMed ID: 37188939
[TBL] [Abstract][Full Text] [Related]
49. CSF1R/CD115 is a Helpful Marker for the Distinction of Florid Dermatopathic Lymphadenopathy From Langerhans Cell Neoplasms.
Ozkaya N; Lee I; Johnson TS; Jaffe ES
Am J Surg Pathol; 2023 Jul; 47(7):844-846. PubMed ID: 37132506
[No Abstract] [Full Text] [Related]
50. Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
[TBL] [Abstract][Full Text] [Related]
51. A solitary osteolytic lesion with pathological fracture in the cervical spine - a case report.
Kuang GM; Loo NN; Gao Q; Li J; Luo L; Chen S; Cheung JPY; Cheung KMC
BMC Musculoskelet Disord; 2023 May; 24(1):436. PubMed ID: 37254107
[TBL] [Abstract][Full Text] [Related]
52. Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.
Gao XM; Li J; Cao XX
Cell Commun Signal; 2022 Dec; 20(1):195. PubMed ID: 36536400
[TBL] [Abstract][Full Text] [Related]
53. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis.
Chen J; Zhao AL; Duan MH; Cai H; Gao XM; Liu T; Sun J; Liang ZY; Zhou DB; Cao XX; Li J
Leukemia; 2022 Feb; 36(2):573-576. PubMed ID: 34611301
[No Abstract] [Full Text] [Related]
54. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
55. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
[TBL] [Abstract][Full Text] [Related]
56. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
Kobayashi M; Tojo A
Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
[TBL] [Abstract][Full Text] [Related]
57. Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis.
Krooks J; Minkov M; Weatherall AG
J Am Acad Dermatol; 2018 Jun; 78(6):1035-1044. PubMed ID: 29754885
[TBL] [Abstract][Full Text] [Related]
58. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
59. Mediastinal Rosai-Dorfman Disease with KRAS mutation case report and literature review.
Zhang W; Fang L; Wang J; Ma X; Hu X; Liu W
J Cardiothorac Surg; 2024 Apr; 19(1):166. PubMed ID: 38561747
[TBL] [Abstract][Full Text] [Related]
60. Langerhans cell histiocytosis of the skull in 23 children.
Wei M; Jiang W; Wang R; Xiao B; Zhan Q
Eur J Med Res; 2024 Feb; 29(1):136. PubMed ID: 38368348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
